Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Patch Heat Bioavailability
NCT03915626Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Total Area Under the Curve 0-12 Hours. Started Oct 2019; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT03915626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915626.